

MISSION

XEPTAGEN is engaged in the development, production and marketing of innovative IVD devices for the early detection of cancer. **XEPTAGEN** has reached these results through the proprietary discovery of novel biomarkers that, either alone or combined with other known biomarkers, lead to an earlier and more precise detection of different forms of cancer. Further work is taking place to produce biochips for the simultaneous detection of these novel biomarkers associated to IgM and forming immune-complexes for the diagnosis of several cancer forms.

CONTACT

XEPTAGEN SpA

VEGA Science Park - Building Auriga
 Via delle Industrie, 9
 30175 Marghera (VE) - Italy

Phone: +39 041 509 3910
 Fax: +39 041 509 3884

info@xeptagen.com
 www.xeptagen.com

PIPELINE

	Biomarkers	Indication	Identification of Marker	Validation of Marker	Prototype Test	Pilot Study	Test Development	Pre-Clinical Study	Clinical Study	IVD Commercialization
ELISA kits	SCCA-IgM	Sclerodermia	█	█	█	█	█	█	█	█
		Pulmonary Cancer	█	█	█	█	█	█	█	█
		Esophageal Cancer	█	█	█	█	█	█	█	█
		Cervical Cancer	█	█	█	█	█	█	█	█
	DCP-IgM	Liver Cancer	█	█	█	█	█	█	█	█
	CA15.3-IgM	Breast Cancer	█	█	█	█	█	█	█	█
	CA19.9-IgM	Colorectal Cancer	█	█	█	█	█	█	█	█
	VEGF-IgM	Liver Cancer	█	█	█	█	█	█	█	█
	GPC3-IgM	Liver Cancer	█	█	█	█	█	█	█	█
	Osteopontin-IgM	Liver Cancer	█	█	█	█	█	█	█	█
BIOCHIP	compleXima® HCC biochip	Liver Cancer	█	█	█	█	█	█	█	█
		compleXima® CRC biochip	Colon Cancer	█	█	█	█	█	█	█
		compleXima® Multi-marker biochip	Prostate, Liver, Breast, Colon	█	█	█	█	█	█	█
	compleXima® HCC biochip	Liver Cancer	█	█	█	█	█	█	█	█
		compleXima® CRC biochip	Colon Cancer	█	█	█	█	█	█	█
		compleXima® Multi-marker biochip	Prostate, Liver, Breast, Colon	█	█	█	█	█	█	█
		compleXima® Multi-marker biochip	Prostate, Liver, Breast, Colon	█	█	█	█	█	█	█

ON THE MARKET

HEPA-IC

ELISA Kit for the detection of Squamous Cell Carcinoma Antigen (SCCA) variants Immune Complexes (SCCA-IgM) in Hepatocellular Carcinoma (HCC)

References

Beneduce L, et al. *Cancer*; 103:2558-65, 2005.
 Pontisso P, et al. *Int. J. Cancer*; 19:735-40, 2006.
 Biasiolo A, et al. *J. Viral Hepat*; 15:246-9, 2008.

Biological Figures

- 70% sensitivity, 100% specificity over healthy control
- Predicts chronic hepatitis & cirrhotic patient evolution
- Detects CH patients response to interferon and lamivudine

COLON-IC

ELISA Kit for the detection of Carcinoembryonic Antigen (CEA) Immune Complexes (CEA-IgM) in Colon Rectal Cancer (CRC)

References

Castaldi F, et al. *Int. J. Biol. Markers*; 20: 204-8, 2005.
 Kojima T, et al. *Mol. Med. Rep.*; 2:477-80, 2009.

Biological Figures

- Detects 29% of patients in stage I Colorectal Cancer
- Combined with CEA determination, raises sensitivity to 60%

PROSTATE-IC

ELISA kit for the assessment of Prostate Specific Antigen (PSA) Immune Complexes (PSA-IgM) in Prostate Cancer (PCa)

References

Beneduce L, et al. *Cancer Detect Prev*; 31 (5): 402-7, 2007.
 Zani D, et al. *Annual Congress SIU, Rimini*, October 4-7, 2009.

Biological Figures

- 40% sensitivity, 88% specificity in differentiating patients with prostate cancer from patients with benign prostatic hyperplasia
- more accurate compared to the analysis of circulating levels of PSA